On Tuesday, in the course of current trade, Shares of Allscripts Healthcare Solutions Inc (NASDAQ:MDRX), climbed 3.33%, and is now trading at $14.59.
Allscripts client Atlantic General Hospital, located in Berlin, Maryland, U.S.A., achieved Stage 6 on the HIMSS Analytics EMR Adoption ModelSM (EMRAM) using the Allscripts Sunrise acute electronic health record (EHR).
The HIMSS Analytics EMR Adoption Model measures progress and the cumulative capabilities of EMR systems within hospitals. There are eight stages (0-7) in the HIMSS Analytics EMR Adoption Model, and 17.9% of hospitals in the HIMSS Analytics(R) Database have presently reached Stage 6. Hospitals that reach Stage 6 have established clear aims for improving safety, minimizing errors, and prioritizing IT implementations.
Allscripts Healthcare Solutions, Inc. provides clinical, financial, electronic health records (EHR), connectivity, hosting, outsourcing, analytics, patient engagement, and population health products and services in the United States and Canada.
During an Afternoon trade, Shares of Microchip Technology Inc. (NASDAQ:MCHP), climbed 0.36%, and is now trading at $47.74.
Microchip Technology, declared that Kia Motors Corporation is enriching its infotainment system with powerful smart-phone connectivity in its flagship Kia K900 luxury sedan (known as ‘Quoris’ in some countries), using Microchip’s OS81110 Intelligent Network Interface Controller (INIC). Building on years of experience using Microchip’s MOST® INICs, Kia adopted the latest MOST150 standard for the 2015 K900 in order to take advantage of its Internet-connectivity capabilities.
To date, more than 170 million MOST interface controllers have been installed in 184 car models since 2001. Kia and all major carmakers have for many years successfully implemented MOST technology in their multi-node infotainment networking systems, as it provides a field-proven, low-risk, whole-system solution. The MOST150 standard meets Kia’s Internet-connectivity requirements. This latest version of MOST technology continues to predictably and efficiently transport video, audio, packet and control data throughout the vehicle without time-synchronization protocols, using dedicated channels for minimal processor overhead in the main infotainment control unit processors.
Microchip Technology Incorporated develops, manufactures, and sells semiconductor products for various embedded control applications. The company offers microcontrollers, such as 8-bit, 16-bit, and 32-bit microcontrollers under the PIC brand name; and 16-bit dsPIC digital signal controllers, in addition to provides microcontrollers for automotive networking, computing, lighting, power supplies, wireless communication, and wireless audio applications.
Shares of Oragenics Inc (NYSEMKT:OGEN), during its Tuesday’s current trading session fell -16.82%, and is now trading at $ 1.8201.
Oragenics Inc, declared a new Exclusive Channel Partnership (ECC) to pursue development of biotherapeutics for oral mucositis (OM) and other diseases and conditions of the oral cavity, throat, and esophagus, counting clinical advancement of the ActoBiotic AG013 for the treatment of OM. OM results in the painful inflammation and ulceration of the membranes lining the oral cavity, throat, and esophagus and is among the most frequently stated adverse events associated with cancer therapy affecting up to 500,000 patients annually. At present there is no drug approved to prevent the condition broadly and therapies are primarily palliative, alleviating symptoms without addressing the underlying pathology, resulting in a noteworthy unmet medical need.
“We are eager to advance therapeutic programs through the established clinical foundations of the ActoBiotics platform, and moving forward in the clinic with AG013 is a natural fit for our focus on the treatment of oral cavity diseases with innovative biopharmaceuticals,” said Frederick Telling, Ph.D., Chairman of the Board of Oragenics. “Work continues under our current partnership with Intrexon centered on the development of a novel class of antibiotics known as lantibiotics, and we are excited to build on this relationship in the field of oral health to realize the promise of microbial approaches in the generation of efficacious new medicines.”
Oragenics, Inc. develops, markets, and sells oral probiotics products and antibiotics for humans and companion pets. The company develops and markets probiotic products comprising ProBiora3, ProBiora3, a blend of oral care probiotics that promote fresher breath, whiter teeth, and support oral health under the Evora and ProBiora brands.
Finally, Maxim Integrated Products Inc. (NASDAQ:MXIM), lost -0.44% Tuesday.
Maxim Integrated Products, makes it easy to calibrate a consumable medical sensor and to monitor or control unsanitary reuse of medical disposables with the DS28E80 gamma-radiation-resistant, nonvolatile (NV) 1-Wire memory.
Gamma radiation sterilization is typically used on single-use disposable medical sensors and consumables because the method is predictable, reliable, faster to process, and usable across a wide array of product materials and packaging types. But, gamma radiation is incompatible with traditional floating-gate memory technologies used in semiconductors because gamma’s high-ionizing radiation erases the memory. The new DS28E80 NV memory, however, is resistant to gamma radiation up to 75kGy (kilo gray). With flexible programming options, it allows OEMs to factory calibrate their sensors, tools, and accessories to their host medical instrument in the field. It can be used to monitor or even prevent unsanitary reuse of a disposable medical sensor and consumables. It operates over the company’s trusted 1-Wire interface, so consumable manufacturers can replace multiple cumbersome cables with a single contact.
Maxim Integrated Products, Inc. designs, develops, manufactures, and markets various linear and mixed-signal integrated circuits worldwide. The company also provides a range of high-frequency process technologies and capabilities for use in custom designs.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
